Bayer AG Stock
€26.29
Your prediction
Bayer AG Stock
Bayer is a multinational pharmaceutical and life sciences company headquartered in Germany. The company was founded in 1863 and has since grown to become a global leader in the fields of pharmaceuticals, agriculture, and consumer health. Bayer is listed on the Frankfurt Stock Exchange and also trades over-the-counter in the United States under the ticker symbol BAYZF. The company's products include prescription drugs, over-the-counter medicines, and agrochemicals, and it operates in more than 90 countries around the world.
Pros and Cons of Bayer AG in the next few years
Pros
Cons
Performance of Bayer AG vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Bayer AG | -0.720% | -2.504% | -5.262% | 7.373% | 36.121% | -51.655% | -38.320% |
| Merck KGaA | -0.820% | -3.212% | -7.602% | -27.297% | -20.949% | -32.886% | -19.325% |
| Elanco Animal Health Inc. | -0.540% | -3.310% | 5.858% | 38.353% | 60.876% | 41.947% | -27.131% |
| Johnson & Johnson | -0.720% | -1.526% | -0.493% | 11.194% | 15.991% | -6.611% | 34.680% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Bayer, with its US ticker symbol BAYZF, is a prominent player in the pharmaceuticals industry, boasting a rich history and a diverse portfolio. A deep dive into Bayer's financials reveals a complex picture—while there are some strengths and opportunities for growth, several areas raise concerns.
When analyzing Bayer's financials, several key aspects come into play, revealing both positives and negatives that deserve attention. The company's total assets stood at approximately €123.34 billion in 2023, slightly up from €124.88 billion in 2022. A noticeable highlight is Bayer’s gross profit, which peaked at around €27.8 billion in 2023, reflecting robust revenue generation capabilities even amidst some operational challenges.
*Pros: *
Comments
News
Dr. Judith Hartmann to Become New Chief Financial Officer of Bayer AG
The Supervisory Board of Bayer AG has appointed Dr. Judith Hartmann to the company’s Board of Management, effective March 1, 2026. She will succeed Wolfgang Nickl as the company’s Chief Financial
KERENDIA® (finerenone) Meets Primary Endpoint in Phase III Clinical Trial for Adults with Type 1 Diabetes and Chronic Kidney Disease
Bayer today announced new Phase III investigational data from the pivotal FINE-ONE trial showing that KERENDIA® (finerenone) significantly reduced urine albumin-to-creatinine ratio (UACR) from
Bayer’s Lynkuet® (elinzanetant), the First and Only Neurokinin 1 and Neurokinin 3 Receptor Antagonist, Receives FDA Approval for Moderate to Severe Hot Flashes Due to Menopause
Bayer announced today the U.S. Food and Drug Administration (FDA) has approved Lynkuet® (elinzanetant) 60mg capsules, the first and only dual neurokinin (NK) targeted therapy,1 neurokinin 1 (NK1)